[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652864":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":11,"responsibleParty":47,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":74,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":11},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants receiving GSK5784283 plus standard of care","EXPERIMENTAL",null,[13,14],"Drug: GSK5784283","Drug: Standard of care",{"label":16,"type":17,"description":11,"interventionNames":18},"Participants receiving matching placebo plus standard of care","PLACEBO_COMPARATOR",[19,14],"Drug: Placebo",[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","GSK5784283","GSK5784283 will be administered.",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Placebo","Placebo will be administered.",[16],{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"Standard of care","Standard of care will be administered.",[9,16],[35],{"name":36,"affiliation":5,"role":37},"GSK Clinical Trials","STUDY_DIRECTOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":45,"role":41,"phone":46,"phoneExt":11,"email":43},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100652864","phase-3-a-study-to-investigate-the-efficacy-and-safety-of-gsk5784283-felcorekibart-compared-with-placebo-in-participants-with-moderate-to-very-severe-copd-persist-copd-1-100652864",false,"NCT07780669","A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-1)","Inclusion Criteria:\n\n* Male or eligible female participants\n* Participants with \\>=40 to less than or equal to (\\\u003C=) 80 years of age.\n* An eosinophilic phenotype with elevated BEC.\n* Moderate to very severe COPD with frequent exacerbations.\n* Participants with elevated COPD assessment test (CAT) score.\n* Current or former cigarette smokers.\n* On triple (Inhaled corticosteroid \\[ICS\\]+ Long-acting muscarinic antagonist \\[LAMA\\]+ Long-acting beta-agonist \\[LABA\\]) or dual inhaled COPD therapy, if ICS is considered not appropriate.\n\nExclusion Criteria:\n\n* Current or prior physician diagnosis of asthma\n* Other clinically significant lung disease.\n* Pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1.\n* Participants with a history of, or plan for lung volume reduction surgery \u002F endobronchial valve procedure.\n* Continuous oxygen therapy (more than 16 hours\u002F day).\n* Cor pulmonale resulting in right heart failure and severe pulmonary hypertension.\n* A current malignancy or history of malignant neoplasm within the last 5 years (except definitively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix).\n* Myocardial infarction, unstable angina or stroke within 6 months of screening, unstable arrhythmia.\n* New York Heart Association class III or IV heart failure.\n* Other significant medical conditions that could impact participants' safety or study outcomes.","ALL","40 Years","80 Years",{"count":60,"type":61},624,"ESTIMATED","INTERVENTIONAL",[64],"PHASE3","The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.",[67],"Pulmonary Disease, Chronic Obstructive",[69,23,70,71,72,73],"Chronic obstructive pulmonary disease","Eosinophilic phenotype","Felcorekibart","Monoclonal antibody","Thymic Stromal Lymphopoietin","NOT_YET_RECRUITING","2026-08-19",{"date":77,"type":78},"2026-08-21","ACTUAL",{"date":80,"type":61},"2026-08-31",{"date":82,"type":61},"2030-03-15",{"name":5,"class":6}]